Updated from 5:05 p.m. EDTWASHINGTON -- Gilead Sciences ( GILD) said third-quarter revenue rose 51% from a year ago, driven by sales of its HIV drugs. Total revenue rose to $493.5 million from $326.2 million a year ago. Product sales climbed 50% to $467.2 million. Gilead earned $179.2 million, or 38 cents a share, in the quarter, up from $113.2 million, or 25 cents a share, a year ago. Analysts surveyed by Thomson First Call expected a profit of 37 cents and sales of $487.6 million. HIV product sales rose 59% to $363.5 million in the third quarter, including $162.4 million from Truvada and $189.4 million from Viread. Gilead has been getting more attention lately because the company's Tamiflu product, co-marketed by Roche, has been discussed as a treatment for avian flu. Bird flu, of course, has become one of the most heavily covered topics by the press in recent weeks, with numerous reports speculating that a pandemic could eventually result if the virus isn't stopped. This past June, Gilead said Roche had breached the companies' Tamiflu marketing agreement. The companies were unable to resolve the dispute and are currently in arbitration. While Gilead, based in Foster City, Calif., declined further comment on the matter, the company said the disagreement won't interfere with any Tamiflu purchases in light of the worries about avian flu. If necessary, Gilead said it and its outside manufacturers will be able to produce "significant quantitites" of the drug. Shares of Gilead were falling $1.33, or 2.8%, to $46.90 in the extra session Tuesday.